Peer-influenced content. Sources you trust. No registration required. This is HCN.

Oncology News Central (ONC)FDA Rejects Tabelecleucel for Post-Transplant Lymphoproliferative Disease

ONC

The FDA’s rejection of tabelecleucel (Ebvallo) for post-transplant lymphoproliferative disease (PTLD) stems from manufacturing site concerns rather than clinical efficacy or safety issues. The allogeneic EBV-specific T-cell immunotherapy, already approved in the EU since 2022, demonstrated promising results in the phase 3 ALLELE trial with a 50.7% overall response rate. Atara Biotherapeutics and Pierre Fabre Laboratories expect to address the manufacturing concerns and resubmit their application within six months.


Key Points:

  • The FDA issued a complete response letter for tabelecleucel’s Biologics License Application, citing manufacturing site-specific concerns without questioning clinical efficacy, safety, or production processes
  • Phase 3 ALLELE trial results showed a 50.7% overall response rate in 75 patients, with median duration of response at 23.0 months and median overall survival of 18.4 months
  • No fatal treatment-related adverse events occurred during the trial, with safety profiles aligning with previous data
  • The therapy targets adults and children over two years with relapsed or refractory EBV+ PTLD
  • Atara anticipates FDA approval within six months of resubmitting the application after addressing manufacturing concerns

PTLD is associated with Epstein-Barr virus (EBV) infection in 60% to 80% of cases, making EBV-directed therapy an attractive treatment modality. (Blood)


Transplant Medicine Summaries

The Healthcare Communications Network is owned and operated by IQVIA Inc.

Click below to leave this site and continue to IQVIA’s Privacy Choices form